Perrigo Company plc PRGO
As ofNov 20, 2026, 1:48 PM EST
- YTD
- +13.29%
- 1 year
- +28.63%
5D -0.44 (-2.64%)
- Market cap
- 2.19B
- Revenue (ttm)
- 4.09B
- Profit margin
- -43.27%
- EPS (ttm)
- -12.47
- Shares out
- 138.80M
- Forward P/E
- 6.99
- Dividend
- 1.16 (7.36%)
- Ex-dividend date
- Nov 27, 2026
- YTD return
- +13.29%
- 1-year return
- +28.63%
- Volume
- 823.84K
- Avg volume
- 2.55M
- Open
- 16.00
- Previous close
- 16.04
- Day's range
- 15.53 – 16.40
- 52-week range
- 9.23 – 17.07
- Beta
- 0.69
- Analysts
- Buy
- Price target
- 18.00 (+14.1%)
- Earnings date
- Feb 25, 2027
Key statistics
- 50-day average
- 15.27
- 200-day average
- 12.55
- Enterprise value
- 5.38B
- PEG ratio
- 1.14
- Price / sales
- 0.54
- Price / book
- 0.91
- Payout ratio
- 1348.75%
- Revenue growth
- -5.20%
- Free cash flow
- 723.45M
- Total cash
- 436.60M
- Total debt
- 3.46B
- Return on equity
- -50.25%
- Short % of float
- 27.19%
Fundamental scorecard
8 of 25 checks passed on PRGO’s reported financials
8of 25 checks passed
- Value 3 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 1 of 5
- Dividend 4 of 5
Statements to Sep 26, 2026.
Analyst view
Consensus: buy
- Target (low)
- 15.00
- Target (mean)
- 18.00
- Target (high)
- 20.00
- Strong buy0
- Buy1
- Hold3
- Sell0
- Strong sell0
Next earnings
Feb 25, 2027
Expected Feb 25, 2027. Consensus EPS estimate 0.81804.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 25, 2027 | Dec 26, 2026 | 0.77 | — | — | — |
| Nov 4, 2026 | Sep 26, 2026 | 0.511 | 0.60 | +0.09 | +17.42% |
| Aug 5, 2026 | Jun 27, 2026 | 0.388 | 0.50 | +0.11 | +28.87% |
| May 6, 2026 | Mar 28, 2026 | 0.39 | 0.43 | +0.04 | +10.26% |
| Feb 26, 2026 | Dec 31, 2025 | 0.80 | 0.77 | -0.03 | -3.75% |
| Nov 5, 2025 | Sep 27, 2025 | 0.75 | 0.80 | +0.05 | +6.67% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 30, 2026 | Canaccord Genuity | main | Buy | Buy |
| Feb 27, 2026 | Canaccord Genuity | main | Buy | Buy |
| Dec 15, 2025 | JP Morgan | main | Neutral | Neutral |
| Nov 6, 2025 | Canaccord Genuity | main | Buy | Buy |
| Nov 6, 2025 | JP Morgan | down | Overweight | Neutral |
| Oct 27, 2025 | Jefferies | main | Hold | Hold |
About Perrigo Company plc
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Ireland
- Website
- perrigo.com
News
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Perrigo Q3 2026 Earnings Call Transcript Perrigo Narrows FY2026 Adj EPS Guidance from $2.25-$2.55 to $2.25-$2.45 vs $2.18 Est; Lowers FY2026 Sales Guidance from $4.019B-$4.189B to $4.011B-$4.057B vs $4.054B Est
Perrigo Q3 Adj. EPS $0.60 Beats $0.50 Estimate, Sales $989.000M Beat $987.200M Estimate
Canaccord Genuity Maintains Buy on Perrigo, Raises Price Target to $19
Perrigo To Sell Infant Formula Business To MeridianMade For Up To $175M; Co To Refocus On Consumer Self-Care Products
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Your note
Sign in to keep a note on PRGO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALFORD BRADLEY A | Director | Conversion of Exercise of derivative security | Sep 10, 2026 | 46,121 |
| ASHFORD ORLANDO D | Director | Conversion of Exercise of derivative security | May 13, 2026 | 27,717 |
| BEZERRA EDUARDO GUARITA | Chief Financial Officer | Conversion of Exercise of derivative security | Jun 4, 2026 | 84,700 |
| JANISH RONALD CRAIG | Chief Technology Officer | Conversion of Exercise of derivative security | Apr 3, 2025 | 35,558 |
| KARABOUTIS ADRIANA | Director | Conversion of Exercise of derivative security | May 13, 2025 | 27,629 |
| LOCKWOOD-TAYLOR PATRICK | Former | Conversion of Exercise of derivative security | Jun 4, 2026 | 123,170 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 16.85% | 23,388,523 | 375.39M | Sep 29, 2026 |
| Neuberger Berman Group, LLC | 7.44% | 10,331,539 | 165.82M | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 6.54% | 9,071,446 | 145.60M | Sep 29, 2026 |
| State Street Corporation | 6.22% | 8,638,060 | 138.64M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 4.52% | 6,269,004 | 100.62M | Sep 29, 2026 |
| FMR, LLC | 4.50% | 6,247,989 | 100.28M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.95% | 8,259,312 | 132.56M | Sep 29, 2026 |
| UNDISCOVERED MANAGERS Fd.S-Undiscovered Managers Behavioral Value Fd. | 4.26% | 5,906,436 | 94.80M | Jun 29, 2026 |
| T. Rowe Price Mid-Cap Value Fund, Inc. | 3.27% | 4,541,190 | 72.89M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.17% | 4,399,261 | 70.61M | Jun 29, 2026 |
| Invesco Exch-Trd Fd. TRT-Invesco High Yield Eqy. Dividend Achievers ET | 2.75% | 3,823,397 | 61.37M | Aug 30, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.63% | 3,644,909 | 58.50M | Sep 29, 2026 |
